Gene · 2829
NIH grants1,173
NIH grants whose papers are about the gene, through NIH's grant-paper links.
401 to 420 of 1,173
Download this page as JSON| Grant | Title | XCR1 papers | Newest fiscal year |
|---|---|---|---|
| F30CA236182 | Structure-Function Investigation of Chemokine-GPCR Signaling in Tumor Progression and Metastasis | 3 | 2023 |
| R01AI150297 | Function of Wdfy4 in cross-presentation and immunity | 3 | 2023 |
| R01AR073252 | IL-26 in host defense against infection by intracellular bacteria in skin | 3 | 2023 |
| R01CA230610 | Regulation of dendritic cell function and tumor immunity by TIM-3 | 3 | 2023 |
| P01AG003991 | Healthy Aging and Senile Dementia | 2 | 2023 |
| P01AG017242 | DNA Repair, Mutations and Cellular Aging | 2 | 2023 |
| R01AI101047 | Novel Influenza nano vaccines for broad cross protection | 2 | 2023 |
| R01AR075959 | Harnessing Human Dendritic Cell Subsets in Skin for the Design of Novel Immunotherapies | 2 | 2023 |
| R01CA177670 | The Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic Cancer | 2 | 2023 |
| R01CA240924 | Reverse transcriptase inhibitor effects on the mobilome of colon cancer | 2 | 2023 |
| U19AI062629 | Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax | 2 | 2023 |
| ZIABC010015 | The Role of Cellular Receptors Involved in Inflammation and Tumor Progression | 2 | 2023 |
| ZIABC010725 | Role of Formylpeptide Receptors in Host Defense | 2 | 2023 |
| F30CA254087 | Harnessing Dendritic Cells as a Novel Therapy in Pancreatic Ductal Adenocarcinoma | 1 | 2023 |
| I21RX003447 | Mechano-active annular repair device for treating disc herniation | 1 | 2023 |
| K01AG059898 | DNA methylation markers of Multimorbidity in Aging Humans and Mice | 1 | 2023 |
| K08AR075880 | Elucidating the role of type 2 immunity in skin homeostasis | 1 | 2023 |
| K08CA241319 | Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sites | 1 | 2023 |
| K23DK111995 | Assessing Predictors of Response to Anti-Tumor Necrosis Alpha Therapy in Early Crohns Disease | 1 | 2023 |
| KL2TR003143 | Institutional Career Development Core (KL2) | 1 | 2023 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2829/grants?page=21